Achieving sufficient delivery across the blood–brain barrier is a key challenge in the
development of drugs to treat central nervous system (CNS) disorders. This is particularly …

Adeno-associated virus (AAV) has emerged as a leading platform for gene delivery for
treating various diseases due to its excellent safety profile and efficient transduction to …

SARS-CoV-2 has been reported to show a capacity for invading the brains of humans and
model animals. However, it remains unclear whether and how SARS-CoV-2 crosses the …

There has been a resurgence in gene therapy efforts that is partly fueled by the identification
and understanding of new gene delivery vectors. Adeno-associated virus (AAV) is a non …

The development of gene therapies for the treatment of diseases of the central nervous
system has been hindered by the limited availability of adeno-associated viruses (AAVs) that …

Efficient delivery of gene therapy vectors across the blood-brain barrier (BBB) is the holy
grail of neurological disease therapies. A variant of the neurotropic vector adeno-associated …

Treatment of certain central nervous system disorders, including different types of cerebral
malignancies, is limited by traditional oral or systemic administrations of therapeutic drugs …

Parvoviruses are a diverse family of small, non-enveloped DNA viruses that infect a wide
variety of species, tissues and cell types. For over half a century, their intriguing biology and …

The integrity of the blood–brain barrier (BBB) is essential for normal central nervous system
(CNS) functioning. Considering the significance of BBB in maintaining homeostasis and the …

Viral tracers are important tools for neuroanatomical mapping and genetic payload delivery.
Genetically modified viruses allow for cell-type-specific targeting and overcome many …